专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07736853B2 Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer 有权
标题翻译：雄激素依赖性前列腺癌的诊断方法，进行雄激素停药的前列腺癌和雄激素依赖性前列腺癌
公开(公告)号：US07736853B2
公开(公告)日：2010-06-15
申请号：US11565589
申请日：2006-11-30
申请人： Daniel E. H. Afar , David Agus , David H. Mack
发明人： Daniel E. H. Afar , David Agus , David H. Mack
IPC分类号： C12Q1/68
CPC分类号： C07K14/47 , C12Q1/6886 , C12Q2600/156 , C12Q2600/158 , G01N33/57449 , G01N2500/04
摘要： Described herein are genes whose expression are up-regulated or down-regulated in prostate cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant prostate cancer cells. Related methods and compositions that can be used for diagnosis and treatment of prostate cancer are disclosed. Also described herein are methods that can be used to identify modulators of prostate cancer.
摘要翻译：本文描述的是其表达在前列腺癌中上调或下调的基因。还描述了这样的基因，其表达在耐药前列腺癌细胞中进一步上调或下调。公开了可用于诊断和治疗前列腺癌的相关方法和组合物。本文还描述了可用于鉴定前列腺癌调节剂的方法。

2. 发明申请

US20080138838A1 DIAGNOSIS OF ZD1839 RESISTANT TUMORS 审中-公开
标题翻译： ZD1839抗性肿瘤诊断
公开(公告)号：US20080138838A1
公开(公告)日：2008-06-12
申请号：US11941443
申请日：2007-11-16
申请人： Daniel Afar , David Agus , David H. Mack
发明人： Daniel Afar , David Agus , David H. Mack
IPC分类号： G01N33/574
CPC分类号： C07K14/47 , C07H21/04 , C12Q1/6837 , C12Q1/6886 , C12Q2600/136
摘要： Described herein are genes whose expression are regulated in specific cancers. Related methods and compositions that can be used for diagnosis of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers.
摘要翻译：本文描述的是其表达在特定癌症中调节的基因。公开了可用于诊断这些癌症的相关方法和组合物。本文还描述了可用于鉴定所选癌症的调节剂的方法。

3. 发明申请

US20070104714A1 Composition and method for the treatment of cancer and other physiologic conditins based on modulation of the ppar-gamma pathway and her-kinase axis 审中-公开
标题翻译：基于ppar-gamma途径和her-kinase轴调节的治疗癌症和其他生理条件的组合物和方法
公开(公告)号：US20070104714A1
公开(公告)日：2007-05-10
申请号：US10568669
申请日：2004-08-27
申请人： David Agus , Anjali Jain , Michael Hedvat
发明人： David Agus , Anjali Jain , Michael Hedvat
IPC分类号： A61K39/395 , A61K31/60 , A61K31/405 , A61K31/192
CPC分类号： A61K45/06 , A61K31/19 , A61K31/192 , A61K31/405 , A61K31/407 , A61K31/47 , A61K31/60 , A61K39/395 , A61K39/39558 , A61K2039/505 , C07K16/3069 , C07K16/32 , C07K2317/24 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： Described herein are methods of using a NSAID and a HER-kinase axis inhibitor in the treatment of various conditions including cancer, and especially prostate, breast, lung, ovarian, brain and colon cancers, through regulation of PPARγ activity. In various embodiments, the NSAID and HER-kinase axis inhibitor may be included in a composition that is useful for the treatment of conditions in a mammal. Also described is a kit including a NSAID and a HER-kinase axis inhibitor along with instructions for their use in treating and preventing disease conditions, such as cancer.
摘要翻译：本文描述的是通过调节PPARγ活性来使用NSAID和HER-激酶轴抑制剂治疗各种疾病，包括癌症，特别是前列腺，乳腺，肺癌，卵巢癌，脑癌和结肠癌的方法。在各种实施方案中，NSAID和HER-激酶轴抑制剂可以包含在可用于治疗哺乳动物中的病症的组合物中。还描述了一种试剂盒，其包括NSAID和HER-激酶轴抑制剂以及其用于治疗和预防疾病状况如癌症的说明书。

4. 发明申请

US20070141621A1 Method Of Screening For Sensitivity To Kinase Inhibitor Therapy 失效
标题翻译：筛选敏感性的激酶抑制剂治疗方法
公开(公告)号：US20070141621A1
公开(公告)日：2007-06-21
申请号：US11678420
申请日：2007-02-23
申请人： David Agus
发明人： David Agus
IPC分类号： C12Q1/68
CPC分类号： C12Q1/485 , A61K31/00 , A61K31/5377 , G01N33/574 , G01N33/57423 , G01N33/57434 , G01N2800/52
摘要： Described herein are methods for treating cancer and other disease conditions in individuals who have either developed a resistance to conventional tyrosine kinase inhibitor (TKI) therapy or who are non-responsive ab initio to conventional TKI therapy. In various embodiments, the methods include administering to a patient a resistance-surmounting quantity of a TKI on a weekly or semi-weekly basis. Alternate embodiments of the present invention include a diagnostic method for assessing an individual's probability of being resistant to TKI therapy, based upon an expression level of epithelial membrane protein-1 (EMP-1); one of the genes believed to be responsible for TKI resistance. The methods of the present invention may be particularly useful in the treatment of lung, breast, prostate, ovarian, brain and colon cancers. The methods of the present invention may be effective in blocking the HER-2 kinase domain either in addition to or in lieu of blocking the EGFR kinase domain.
摘要翻译：本文描述的是用于治疗已经对常规的酪氨酸激酶抑制剂（TKI）治疗产生耐药性或从起始于常规TKI治疗无效的个体中治疗癌症和其它疾病状况的方法。在各种实施方案中，所述方法包括以每周或半周为基础向患者施用抗T-T的抵抗量。基于上皮膜蛋白-1（EMP-1）的表达水平，本发明的替代实施方案包括用于评估个体耐TKI治疗的可能性的诊断方法; 据信是对TKI抗性负责的一个基因。本发明的方法可以特别用于治疗肺，乳腺，前列腺，卵巢，脑和结肠癌。除了或代替阻断EGFR激酶结构域之外，本发明的方法可有效阻断HER-2激酶结构域。

5. 发明申请

US20070161016A1 METHODS OF DIAGNOSIS OF ANDROGEN-DEPENDENT PROSTATE CANCER, PROSTATE CANCER UNDERGOING ANDROGEN WITHDRAWAL, AND ANDROGEN-INDEPENDENT PROSTATE CANCER 有权
标题翻译：诊断依赖于原发性癌的方法，前列腺癌和恶性肿瘤前列腺癌和独立前列腺癌
公开(公告)号：US20070161016A1
公开(公告)日：2007-07-12
申请号：US11565589
申请日：2006-11-30
申请人： Daniel Afar , David Mack , David Agus
发明人： Daniel Afar , David Mack , David Agus
IPC分类号： C12Q1/68
CPC分类号： C07K14/47 , C12Q1/6886 , C12Q2600/156 , C12Q2600/158 , G01N33/57449 , G01N2500/04
摘要： Described herein are genes whose expression are up-regulated or down-regulated in prostate cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant prostate cancer cells. Related methods and compositions that can be used for diagnosis and treatment of prostate cancer are disclosed. Also described herein are methods that can be used to identify modulators of prostate cancer.
摘要翻译：本文描述的是其表达在前列腺癌中上调或下调的基因。还描述了这样的基因，其表达在耐药前列腺癌细胞中进一步上调或下调。公开了可用于诊断和治疗前列腺癌的相关方法和组合物。本文还描述了可用于鉴定前列腺癌调节剂的方法。

6. 发明申请

US20060134115A1 Method of screening for sensitivity to kinase inhibitor therapy 审中-公开
标题翻译：筛选激酶抑制剂治疗敏感性的方法
公开(公告)号：US20060134115A1
公开(公告)日：2006-06-22
申请号：US11359826
申请日：2006-02-22
申请人： David Agus
发明人： David Agus
IPC分类号： A61K39/395
CPC分类号： C12Q1/485 , A61K31/00 , A61K31/5377 , G01N33/574 , G01N33/57423 , G01N33/57434 , G01N2800/52
摘要： Described herein are methods for treating cancer and other disease conditions in individuals who have either developed a resistance to conventional tyrosine kinase inhibitor (TKI) therapy or who are non-responsive ab initio to conventional TKI therapy. In various embodiments, the methods include administering to a patient a resistance-surmounting quantity of a TKI on a weekly or semi-weekly basis. Alternate embodiments of the present invention include a diagnostic method for assessing an individual's probability of being resistant to TKI therapy, based upon an expression level of epithelial membrane protein-1 (EMP-1); one of the genes believed to be responsible for TKI resistance. The methods of the present invention may be particularly useful in the treatment of lung, breast, prostate, ovarian, brain and colon cancers. The methods of the present invention may be effective in blocking the HER-2 kinase domain either in addition to or in lieu of blocking the EGFR kinase domain.
摘要翻译：本文描述的是用于治疗已经对常规的酪氨酸激酶抑制剂（TKI）治疗产生耐药性或从起始于常规TKI治疗无效的个体中治疗癌症和其它疾病状况的方法。在各种实施方案中，所述方法包括以每周或半周为基础向患者施用抗T-T的抵抗量。基于上皮膜蛋白-1（EMP-1）的表达水平，本发明的替代实施方案包括用于评估个体耐TKI治疗的可能性的诊断方法; 据信是对TKI抗性负责的一个基因。本发明的方法可以特别用于治疗肺，乳腺，前列腺，卵巢，脑和结肠癌。除了或代替阻断EGFR激酶结构域之外，本发明的方法可有效阻断HER-2激酶结构域。

7. 发明申请

US20050059012A1 Diagnosis of ZD1839 resistant tumors 审中-公开
标题翻译：诊断ZD1839耐药性肿瘤
公开(公告)号：US20050059012A1
公开(公告)日：2005-03-17
申请号：US10633486
申请日：2003-07-31
申请人： Daniel Afar , David Agus , David Mack
发明人： Daniel Afar , David Agus , David Mack
IPC分类号： C07H21/04 , C07K14/47 , C12Q1/68 , C12N9/00
CPC分类号： C07K14/47 , C07H21/04 , C12Q1/6837 , C12Q1/6886 , C12Q2600/136
摘要： Described herein are genes whose expression are regulated in specific cancers. Related methods and compositions that can be used for diagnosis of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers.
摘要翻译：本文描述的是其表达在特定癌症中调节的基因。公开了可用于诊断这些癌症的相关方法和组合物。本文还描述了可用于鉴定所选癌症的调节剂的方法。

8. 发明公开

US20240208985A2 ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS 审中-公开
公开(公告)号：US20240208985A2
公开(公告)日：2024-06-27
申请号：US17913126
申请日：2021-03-22
申请人： Charles McKenna , David Agus
发明人： Charles McKenna , David Agus
IPC分类号： C07D491/08
CPC分类号： C07D491/08
摘要： Herein is reported a class of chiral compounds with paradoxical effects on the androgen receptor (AR). The (R)-enantiomers behave like classical anti-androgens while the (S)-enantiomers activate AR signaling. In castration-resistant prostate cancer, the change during the course of therapy to growth in the presence of AR targeted therapeutics, a harbinger of progression to lethal disease, is commonly attributed to acquired mutations of the AR-ligand binding domain. This is the first report of an antagonist -agonist duality solely due to structural enantiomerism, without any modification to the AR binding site.

9. 发明申请

US20080176229A1 Gene Expression Markers for Response to EGFR Inhibitor Drugs 审中-公开
标题翻译：用于EGFR抑制剂药物的基因表达标记物
公开(公告)号：US20080176229A1
公开(公告)日：2008-07-24
申请号：US11755697
申请日：2007-05-30
申请人： David Agus , Steven Shak , Maureen Cronin , Joffre Baker
发明人： David Agus , Steven Shak , Maureen Cronin , Joffre Baker
IPC分类号： C12Q1/68 , G01N33/574 , C40B40/08 , C12P19/34
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
摘要翻译：本发明涉及与癌症相关的预后标志物。特别地，本发明涉及基于石蜡包埋的癌症组织固定样品中基因表达的分子表征的预后方法，其允许医师预测患者是否可能对EGFR抑制剂治疗反应良好。

10. 发明申请

US20060034840A1 ErbB antagonists for pain therapy 审中-公开
标题翻译：用于疼痛治疗的ErbB拮抗剂
公开(公告)号：US20060034840A1
公开(公告)日：2006-02-16
申请号：US11102120
申请日：2005-04-07
申请人： David Agus
发明人： David Agus
IPC分类号： A61K39/395
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/30 , C07K16/32 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present application describes the use of ErbB antagonist, especially ErbB2 antibodies such as rhuMAb 2C4, for treating pain.
摘要翻译：本申请描述了ErbB拮抗剂，特别是ErbB2抗体如rhuMAb 2C4用于治疗疼痛的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式